JP2015505303A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505303A5 JP2015505303A5 JP2014546471A JP2014546471A JP2015505303A5 JP 2015505303 A5 JP2015505303 A5 JP 2015505303A5 JP 2014546471 A JP2014546471 A JP 2014546471A JP 2014546471 A JP2014546471 A JP 2014546471A JP 2015505303 A5 JP2015505303 A5 JP 2015505303A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- pharmaceutical composition
- lipocalin mutein
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161570018P | 2011-12-13 | 2011-12-13 | |
| US61/570,018 | 2011-12-13 | ||
| PCT/EP2012/075146 WO2013087660A1 (en) | 2011-12-13 | 2012-12-12 | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017067615A Division JP6725447B2 (ja) | 2011-12-13 | 2017-03-30 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505303A JP2015505303A (ja) | 2015-02-19 |
| JP2015505303A5 true JP2015505303A5 (enExample) | 2016-02-04 |
| JP6163162B2 JP6163162B2 (ja) | 2017-07-12 |
Family
ID=47552959
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546471A Expired - Fee Related JP6163162B2 (ja) | 2011-12-13 | 2012-12-12 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
| JP2017067615A Expired - Fee Related JP6725447B2 (ja) | 2011-12-13 | 2017-03-30 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
| JP2019062186A Expired - Fee Related JP6889201B2 (ja) | 2011-12-13 | 2019-03-28 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
| JP2020092168A Pending JP2020164532A (ja) | 2011-12-13 | 2020-05-27 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
| JP2022049676A Active JP7441589B2 (ja) | 2011-12-13 | 2022-03-25 | Ｉｌ－４および／またはｉｌ－１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017067615A Expired - Fee Related JP6725447B2 (ja) | 2011-12-13 | 2017-03-30 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
| JP2019062186A Expired - Fee Related JP6889201B2 (ja) | 2011-12-13 | 2019-03-28 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
| JP2020092168A Pending JP2020164532A (ja) | 2011-12-13 | 2020-05-27 | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
| JP2022049676A Active JP7441589B2 (ja) | 2011-12-13 | 2022-03-25 | Ｉｌ－４および／またはｉｌ－１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9572863B2 (enExample) |
| EP (3) | EP3453400B1 (enExample) |
| JP (5) | JP6163162B2 (enExample) |
| CN (2) | CN103998053B9 (enExample) |
| AU (1) | AU2012350660B2 (enExample) |
| CA (1) | CA2858962C (enExample) |
| DK (2) | DK3453400T3 (enExample) |
| ES (2) | ES2863410T3 (enExample) |
| HU (2) | HUE042720T2 (enExample) |
| PL (2) | PL3453400T3 (enExample) |
| SG (2) | SG11201402992SA (enExample) |
| TR (1) | TR201901826T4 (enExample) |
| WO (1) | WO2013087660A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8986951B2 (en) * | 2010-06-08 | 2015-03-24 | Pieris Ag | Tear lipocalin in muteins binding IL-4 R alpha |
| ES2863410T3 (es) | 2011-12-13 | 2021-10-11 | Pieris Pharmaceuticals Gmbh | Métodos para prevenir o tratar ciertos trastornos mediante la inhibición de la unión de IL-4 y/o IL-13 a sus respectivos receptores. |
| SG10201912019WA (en) * | 2014-05-22 | 2020-02-27 | Pieris Pharmaceuticals Gmbh | Novel specific-binding polypeptides and uses thereof |
| KR20180029238A (ko) * | 2015-07-15 | 2018-03-20 | 피어이스 파마슈티컬즈 게엠베하 | Lag-3에 특이적인 신규 단백질 |
| CN107474134B (zh) | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| WO2018134274A1 (en) | 2017-01-18 | 2018-07-26 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for lag-3 |
| BR112019021812A2 (pt) | 2017-04-21 | 2020-05-26 | Kindred Biosciences, Inc. | Molécula receptora de il4/il13 para uso veterinário |
| CN111494625B (zh) | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物 |
| MA55490A (fr) * | 2019-03-29 | 2022-02-09 | Astrazeneca Ab | Mutéine de lipocaline pour le traitement de l'asthme |
| KR20210146999A (ko) | 2019-03-29 | 2021-12-06 | 피어이스 파마슈티컬즈 게엠베하 | 리포칼린 뮤테인의 흡입 투여 |
| MX2023007174A (es) | 2020-12-18 | 2023-09-08 | Astrazeneca Ab | Formulacion de polvo seco de muteina de lipocalina para el tratamiento del asma. |
| CN115414467B (zh) * | 2022-10-14 | 2023-06-06 | 中国人民解放军陆军军医大学第二附属医院 | 载脂蛋白d在制备治疗脑出血药物中的用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| DE4425255A1 (de) | 1994-07-16 | 1996-01-18 | Asta Medica Ag | Formulierung zur inhalativen Applikation |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6446467B1 (en) | 1997-07-29 | 2002-09-10 | Physical Optics Corporation | Monolithic glass light shaping diffuser and method for its production |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| TR200003635T2 (tr) | 1998-06-08 | 2001-04-20 | F.Hoffmann-La Roche Ag | Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması. |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| DE10043509A1 (de) | 2000-09-01 | 2002-03-14 | Asta Medica Ag | Feste Peptidzubereitungen für die Inhalation und deren Herstellung |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| AU2003233583A1 (en) * | 2002-05-24 | 2003-12-12 | Agennix Incorporated | Oral lactoferrin in the treatment of respiratory disorders |
| AU2003264100A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of a bilin-binding protein with affinity for a given target |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| RU2389796C2 (ru) | 2003-08-29 | 2010-05-20 | Аэровэнс, Инк. | Модифицированный антагонист рецептора il-4 и предназначенный для его получения очищенный полинуклеотид |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| JP2009509535A (ja) | 2005-09-27 | 2009-03-12 | アムニクス， インコーポレイテッド | タンパク様薬剤およびその使用 |
| EP1996613B1 (en) | 2006-03-20 | 2014-04-30 | Technische Universität München | Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4 |
| CN104650213A (zh) * | 2006-08-01 | 2015-05-27 | 皮里斯股份公司 | 泪液脂质运载蛋白的突变蛋白及其获得方法 |
| WO2009009775A1 (en) * | 2007-07-11 | 2009-01-15 | Aerovance, Inc. | Pharmaceutical polypeptide dry powder aerosol formulation and method of preparation |
| US8986951B2 (en) | 2010-06-08 | 2015-03-24 | Pieris Ag | Tear lipocalin in muteins binding IL-4 R alpha |
| ES2863410T3 (es) | 2011-12-13 | 2021-10-11 | Pieris Pharmaceuticals Gmbh | Métodos para prevenir o tratar ciertos trastornos mediante la inhibición de la unión de IL-4 y/o IL-13 a sus respectivos receptores. |
-
2012
- 2012-12-12 ES ES18197286T patent/ES2863410T3/es active Active
- 2012-12-12 SG SG11201402992SA patent/SG11201402992SA/en unknown
- 2012-12-12 PL PL18197286T patent/PL3453400T3/pl unknown
- 2012-12-12 US US14/364,449 patent/US9572863B2/en not_active Expired - Fee Related
- 2012-12-12 EP EP18197286.0A patent/EP3453400B1/en active Active
- 2012-12-12 HU HUE12813295A patent/HUE042720T2/hu unknown
- 2012-12-12 SG SG10201604566QA patent/SG10201604566QA/en unknown
- 2012-12-12 EP EP21152253.7A patent/EP3842058B1/en active Active
- 2012-12-12 HU HUE18197286A patent/HUE054342T2/hu unknown
- 2012-12-12 CN CN201280061754.7A patent/CN103998053B9/zh not_active Expired - Fee Related
- 2012-12-12 TR TR2019/01826T patent/TR201901826T4/tr unknown
- 2012-12-12 JP JP2014546471A patent/JP6163162B2/ja not_active Expired - Fee Related
- 2012-12-12 AU AU2012350660A patent/AU2012350660B2/en not_active Ceased
- 2012-12-12 PL PL12813295T patent/PL2790719T3/pl unknown
- 2012-12-12 CA CA2858962A patent/CA2858962C/en active Active
- 2012-12-12 DK DK18197286.0T patent/DK3453400T3/da active
- 2012-12-12 DK DK12813295.8T patent/DK2790719T3/en active
- 2012-12-12 CN CN201811146540.5A patent/CN109432402B/zh not_active Expired - Fee Related
- 2012-12-12 EP EP12813295.8A patent/EP2790719B1/en active Active
- 2012-12-12 ES ES12813295T patent/ES2710384T3/es active Active
- 2012-12-12 WO PCT/EP2012/075146 patent/WO2013087660A1/en not_active Ceased
-
2016
- 2016-12-02 US US15/367,680 patent/US10016483B2/en active Active
-
2017
- 2017-03-30 JP JP2017067615A patent/JP6725447B2/ja not_active Expired - Fee Related
-
2018
- 2018-06-07 US US16/002,704 patent/US10398754B2/en active Active
-
2019
- 2019-03-28 JP JP2019062186A patent/JP6889201B2/ja not_active Expired - Fee Related
- 2019-07-16 US US16/513,636 patent/US10857202B2/en not_active Expired - Fee Related
-
2020
- 2020-05-27 JP JP2020092168A patent/JP2020164532A/ja active Pending
- 2020-11-05 US US17/090,571 patent/US11382951B2/en active Active
-
2022
- 2022-03-25 JP JP2022049676A patent/JP7441589B2/ja active Active
- 2022-06-14 US US17/839,635 patent/US20230021168A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505303A5 (enExample) | ||
| JP6889201B2 (ja) | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 | |
| JP7169693B2 (ja) | 呼吸器疾患の治療 | |
| CN108778316B (zh) | 糖皮质激素联合聚乙二醇修饰的白介素2治疗呼吸道疾病 | |
| RU2013150249A (ru) | Композиции и способы профилактики или лечения заболеваний, состояний или процессов, характеризуемых аберрантной пролиферацией фибробластов и отложением внеклеточного матрикса | |
| RU2015144185A (ru) | Лечение заболеваний, опосредованных тh2, путем ингибирования бромодоменов | |
| JP2019536812A (ja) | オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ | |
| Ohga et al. | The suppressive effects of YM-58483/BTP-2, a store-operated Ca2+ entry blocker, on inflammatory mediator release in vitro and airway responses in vivo | |
| RU2013157398A (ru) | Композиция | |
| JP2017528454A5 (enExample) | ||
| KR102875179B1 (ko) | 폴리클로날 면역글로불린을 사용한 급성 악화를 예방하거나 치료하기 위한 방법 및 조성물 | |
| CN115697301A (zh) | 用于治疗急性呼吸窘迫综合征、哮喘或变应性鼻炎的制剂和方法 | |
| CN101883566B (zh) | 用于治疗或预防涉及组胺h4受体的病症的美喹他嗪 | |
| JP2016502992A5 (enExample) | ||
| WO2014046624A1 (en) | A method for treating a disease or disorder of the lung by inhibition of the hedgehog pathway | |
| Baradia et al. | Inhalation therapy to treat pulmonary arterial hypertension | |
| Syabbalo | The role of airway remodeling in the pathogenesis and treatment of chronic obstructive pulmonary disease | |
| WO2020247136A2 (en) | USE OF R-ENANTIOMER β2-AGONISTS FOR PREVENT AND TREATMENT OF PULMONARY INFLAMMATION AND INFLAMMATORY REMODELING FOR REDUCED ADVERSE EFFECTS | |
| CN115381843A (zh) | L-岩藻糖在制备呼吸系统疾病治疗药物中的用途 | |
| Nishihara et al. | 155 Omalizumab Improves Asthma but not Nasal Symptoms in Japanese Patients With Severe Allergic Asthma and Rhinitis | |
| Berger et al. | 154 A 26-Week Study Evaluating the Safety and Efficacy of Ciclesonide Hydrofluoralkane Nasal Aerosol in Subjects With Perennial Allergic Rhinitis | |
| HK40001660A (en) | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |